New NK-1 inhibitor HR20013 shows promising results in preventing chemotherapy-induced nausea and vomiting in NSCLC patients

Advancements in paediatric Acute lymphoblastic leukemia management

Enhancing head and neck oncology: Key insights from the conference

Tusamitamab ravtansine versus docetaxel in previously treated advanced nonsquamous NSCLC: Results from phase 3 CARMEN-LC03 trial

Cemiplimab monotherapy could be a new treatment option for first line advanced NSCLC patients

Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients

Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies

Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC

Choosing 1st line TKI Wisely in patients with CML

Common Sense Oncology in head & neck cancers

Head & Neck - BMC Data

Amivantamab-lazertinib continue to show benefit as a first-line standard-of-care for EGFR-mutated advanced NSCLC